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Prescription Drug Monitoring Programs:
Evolution and Evidence

O

verdose deaths from prescription opioids in the U.S. quadrupled from 1999
to 2015, reaching 22,000 in 2015. This increase has been fueled by a dramatic
rise in the amount of opioids being prescribed, creating a vast supply of drugs at
high risk for misuse. Prescribers, therefore, are a vital link in addressing the
current epidemic of overdose deaths and substance use disorders. The challenge is
to develop and implement systems that help prescribers identify potential cases of
misuse or diversion, while still allowing appropriate prescribing of opioids for pain
control.
All states except Missouri now have functioning prescription drug monitoring
programs (PDMPs) that collect data from pharmacies on all dispensed controlled
substances. These statewide databases have many potential uses: they can help
prescribers identify patients who are “doctor-shopping” or who might need
substance use disorder treatment; they can help government agencies and medical
licensure boards monitor prescribing practices and identify unusual prescribing
patterns; and they can inform community-based prevention strategies.
For a PDMP to be effective, however, it must be used. Despite the promise of
PDMPs, actual use of PDMPs by prescribers remained low until recent years. A
2014 national survey found that 72 percent of primary care physicians were aware
of their state’s PDMP, but only 53 percent of primary care physicians ever used it,
and many did not use it routinely. Since then, some states have implemented
mandates for provider participation in PDMPs.

The steep rise in overdose

deaths has been fueled by
the dramatic increase in
opioid prescriptions.

This Issue Brief reviews the current status and characteristics of PDMPs, their use,
and evidence of their effectiveness. It summarizes best practices for PDMPs and
the needs for further research and evaluation.
Current status and characteristics
Not surprisingly, PDMPs have evolved differently across states and over time. Most
states provide access to their PDMP to a wide range of health professionals who
prescribe or dispense controlled substances, including physicians, nurse
practitioners, physician assistants, dentists, pharmacists, and podiatrists. But
PDMPs vary considerably in their data collection, processes, and protocols. In a
2015 survey, more than half of states (26) reported that dispensers must submit
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data daily, while 15 states require weekly input. Fourteen states report some
efforts to integrate their PDMP into a health information exchange or electronic
health record (EHR). Eighteen states report having an enhanced user interface of
some type, such as risk assessment tools or red flags.

Prescriber mandates to
enroll in and use PDMPs

vary significantly by state.

One of the key differences is whether a state requires authorized prescribers and
dispensers to register/enroll in or use the system. This aspect of PDMPs is rapidly
changing; the maps below reflect these differing mandates as of April 2017:
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*Missouri does not have a state PDMP

PDMP Mandatory Query by Prescribers and Dispensers
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While enrollment mandates are generally comprehensive, mandates of use vary in
strength and scope. The Centers for Disease Control and Prevention defines
“universal use” as a requirement that prescribers consult the PDMP before
initially prescribing controlled medication for a given patient and at least every
three months after that; as of July 2015, only four states met that rigorous
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standard. Other states had no requirement for initial prescribing, no requirement
for subsequent checks, or included subjective standards or broad exceptions.
Effectiveness: the latest evidence

The overall effectiveness
of PDMPs is difficult to
ascertain, but recent

The overall effectiveness of PDMPs is difficult to ascertain, given the state-specific
attributes of each system and the evolving nature of state policies and provider
participation.

studies suggest they can

Single state studies have reported some successes, although they suffer from weak
designs and lack of generalizability. One study found that oxycodone-caused
mortality abruptly declined (by 25 percent) in the month after Florida implemented
its PDMP; another study found that Florida’s PDMP was associated with a 1.4
percent decrease in opioid prescriptions and a 2.5 percent decrease in opioid
volume compared to Georgia, effects that were concentrated among the four
percent of Florida providers responsible for 40 percent of opioid prescriptions
at baseline. In New York, a pre-post study found that the PDMP was associated
with a 78 percent reduction in quantity of opioid pills prescribed by dentists in an
urgent care center three months after implementation. In a survey in Maryland, 74
percent of physicians said the PDMP was “very useful” in deciding whether or not
to prescribe opioids and 70 percent reported that they had reduced their opioid
prescribing because of access to a PDMP.

change prescribing
patterns.

In the following section, we focus on the latest studies across states, and what they
reveal about the effects of PDMPs on providers, patients, and health outcomes.
Provider Prescribing Behavior
Bao, Pan, Taylor et al. (2016) used data from the National Ambulatory Medical
Care Survey to assess the effects of PDMPs on prescribing behavior in 24 states
from 2001 to 2010. They found that implementation of a PDMP was associated
with more than a 30 percent drop in the rate of Schedule II opioid prescribing (the
category with the highest potential for abuse). After adjusting for patient and state
attributes, the probability of prescribing a Schedule II opioid at an office visit for
pain went from 5.5 percent to 3.7 percent after implementation of a PDMP. The
effect was seen immediately after the launch of a program and continued in the
second and third years afterward.
Moyo, Simoni-Wastila, Griffin, et al. (2017) looked at the impact of PDMPs on
opioid utilization among Medicare beneficiaries in 10 states that implemented
programs from 2007-2012. Compared to states without programs, PDMP
implementation was associated with reduced prescribed opioid volume (using
cumulative monthly morphine milligram equivalents), but no change in number of
prescriptions, after one year. This suggests shifts in the type or dose of the drugs
prescribed, or changes in the days of supply per prescription. These effects differed
by Medicare eligibility status and plan type, with greater effects on disabled
Medicare beneficiaries (versus elderly ones) and enrollees in Medicare
Advantage plans (versus Medicare Part D plans).
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In a study of Medicare Part D beneficiaries, Yarbrough (2017) found that PDMPs
were associated with a 5.2 percent decrease in days supply prescribed per
physician for oxycodone in addition to smaller reductions for hydrocodone and
opioids overall (2.8 percent and 2 percent, respectively). The effects of PDMPs
were limited to states that mandated use of the PDMP.

Registration mandates,
required nationally, could
save Medicaid $166 million
annually.

Wen, Schackman, Aden & Bao (2017) evaluated the effects of mandates on opioid
prescriptions received by Medicaid enrollees, a population at heightened risks for
prescription opioid misuse and overdose and a priority population for any state
drug control policies. They found that PDMP mandates of any kind implemented
between 2011 and 2014 were associated with a 9-10 percent reduction in the use
of Schedule II opioids by Medicaid enrollees compared to states without mandates.
When the researchers differentiated between registration mandates and use
mandates, they found that the reduction in prescriptions of Schedule II opioids
were largely attributable to mandates of registration. Mandates of use, either alone
or in combination with a mandate of registration, were not associated with
(incremental) reductions in Schedule II opioid prescriptions received by Medicaid
enrollees. The authors estimate that if every state adopted a mandate of
registration, Medicaid programs nationwide could save over $166 million on
Schedule II opioids over a 12-month period. This likely underestimates the full
effect, as Medicaid is also the most common payer of opioid-related
hospitalizations.
Average predicted numbers of prescriptions for Schedule II prescription
opioids per 100 Medicaid enrolees per quarter in states with and without
prescriber mandates, 2011–14

				

Wen et al., Health Affairs 2017; 36: 733-741

Contrary to the common belief that mandates of registration alone might have
limited effects, this study supports adoption of mandates of registration in all states
as an effective and relatively low-cost strategy to enhance prescriber participation
in PDMPs.
Patient Behavior
Meara, Horwitz, Powell, et al. (2016) looked at the impact of a variety of state drug
laws, including PDMPs, on patient behaviors in a high risk population: disabled
fee-for-service Medicare beneficiaries younger than 65 years of age, half of whom
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More robust programs
have been associated with
positive changes in patient
behavior and fewer drug
overdoses.

used opioids in a given year. In an analysis of laws enacted from 2006-2012, they
found that PDMPs were not associated with decreases in the behaviors they are
designed to identify, including measures of doctor shopping and diversion. The
authors acknowledge that the analysis did not account for the robustness of each
state’s PDMP, and that more than 20 states strengthened or enacted mandates
after their study period ended.
An NBER paper by Carey and Buchmueller (2017) sheds light on how the
robustness of a PDMP affects these patient behaviors. The authors compared
Medicare opioid prescription data in 10 states that enacted use mandates from
2007-2013 with 17 other states implementing PDMPs without use mandates. In
states with mandates, the percentage of Medicare enrollees who obtained
prescriptions from five or more doctors was eight percent lower, compared with
other states. The percentage of people getting opioids from five or more
pharmacies was 15 percent lower. The researchers found that most of the effects
were driven by the younger Medicare population on SSI disability, particularly
people who were disabled and had low incomes.
States with use mandates also saw a decline in the number of Medicare enrollees
filling opioid prescriptions before the previous one had run out, or obtaining more
than a seven-month supply of opioids in a half-year period. These states also saw a
15 percent reduction in the number of Medicare enrollees with four or more new
patient visits in six months. The authors estimate that Medicare would save $348
million annually in unnecessary new patient visits if every state mandated use of its
PDMP.
Population Health Outcomes: Drug Overdoses
Using national mortality data from 1999-2008, Li, Brady, Lang, et al. (2014) found
that implementation of a PDMP did not reduce drug overdose deaths in most
states, although the impact varied considerably by state. Meara, Horwitz, Powell, et
al. (2016) found that implementation of a PDMP between 2006-2012 had no effect
on the percentage of younger disabled Medicare beneficiaries treated for nonfatal
prescription opioid overdoses.
Other studies have shown more promising results. Patrick, Fry, Jones & Buntin
(2016) focused on 34 states that had implemented a PDMP from 1999-2013 and
found that a state’s implementation of a program was associated with an average
reduction of 1.12 prescription opioid-related overdose deaths per 100,000
population in the year after implementation. (The states in the study had an
average opioid-related overdose death rate of 6.2 per 100,000 population in 2013.)
Additionally, states whose programs had robust characteristics—including
monitoring greater numbers of drugs with abuse potential and updating their
data at least weekly—had greater reductions in deaths, compared to states whose
programs did not have these characteristics. The authors estimated that if Missouri
adopted a PDMP and other states enhanced their programs with robust features,
there would be more than 600 fewer overdose deaths nationwide in 2016,
preventing approximately two deaths each day.
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Effectiveness of PDMPs
depends on implementation
and use.

Best practices

need further evaluation.

Similarly, Pardo (2017) studied programs between 1999 and 2014, and found that
states that had more robust PDMPs have fewer prescription opioid overdose deaths
than states with weaker ones. He estimated that the more robust programs were
associated with an 18 percent reduction in prescription opioid overdose deaths
compared to no program. Whether some of these deaths avoided may be offset
by individuals overdosing after substituting heroin for prescription opioids requires
further investigation.
Best Practices and Next Steps for PDMPs
PDMPs are works in progress, and their effectiveness depends on how they are
implemented and the extent to which they are used. As the knowledge base and
experience with PDMPs expands, a number of experts have proposed a set of best
practices for states to consider. But as Ashburn (2016) notes, many, if not most,
of these best practices have not yet been shown to improve patient outcomes or
decrease non-medical use of controlled substances.
In 2016, the National Governors’ Association laid out a “road map” for states to use
in addressing the opioid epidemic, and suggested five steps to optimize PDMPs and
improve their effectiveness.
•
•
•
•
•

Require providers to check the PDMP before prescribing controlled
substances.
Use PDMP data to provide proactive analyses and reporting to professional
licensing boards and law enforcement.
Require pharmacists to report to the PDMP within 24 hours.
Make PDMPs easier to use by integrating PDMP data into electronic health
records and health information systems and by allowing prescribers to
establish delegate accounts.
Ensure PDMP interoperability across states.

In recent years, more states are adopting stronger and more comprehensive
mandates of use. But as indicated by Wen, Schackman, Aden & Bao (2017),
mandated registration of providers may have as much or more of an effect. The
added value of mandating use needs to be further assessed as mandate policies
continue to evolve, along with potential unintended consequences such as
excessive infringement on prescriber autonomy. While enforcement of registration
mandates can be relatively low-cost (for example, if paired with prescriber license
renewal), enforcing mandates of use will be costly if not impossible. More research
is needed on the optimal way to improve provider participation in PDMPs, one that
maximizes prescriber buy-in and minimizes other barriers, such as time burden,
password resets, and privacy and security concerns for information on controlled
substance use.
The proactive use of PDMP data for clinical, enforcement and education purposes
has intuitive appeal, although it is largely unexplored. Proactive uses can involve
unsolicited reports or alerts to prescribers and dispensers, the development of
prescriber report cards with peer comparisons, and the use of de-identified data to
identify geographic hot spots and communities at risk. Currently, 12 states are
participating in the Prescription Behavior Surveillance System, a longitudinal
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database of de-identified PDMP data. The effectiveness of this and other
proactive uses of PDMPs has not yet been evaluated.

PDMPs will continue to
evolve as important tools
in the state efforts to

combat the opioid epidemic.

Integrating PDMPs into existing electronic information systems such as EHRs and
pharmacy databases would greatly increase their clinical value, although the lack
of uniform standards across systems is a significant barrier. Demonstration
projects have proven that integration is feasible, albeit on a small scale. From
2012-2016, SAMHSA funded projects in nine states, and the CDC evaluated the
initiative in 2017. Eight states succeeded in some level of integration, and most
reported large increases in queries to the system. Kansas integrated PDMP data
into a health system network, and reported sevenfold increases in solicited
reports from the health system; Washington made its PDMP interoperable with
a statewide Emergency Department Information Exchange, and reported 80-fold
increases in solicited reports from EDs; Illinois integrated its PDMP in a hospital’s
EHR and reported a 145-fold increase in solicited reports, a 22 percent decrease in
the number of opioid prescriptions issued by the hospital’s prescribers, and a 40
percent decrease in the number of patients with at least one opioid prescription.
In the same initiative, Illinois, Kansas, and West Virginia successfully initiated
two-way data exchanges with most of their border states, and reported
increasing amounts of out-of-state data in reports solicited by in-state providers.
Data exchange or interoperability between states could limit patients’ ability to
cross state lines to avoid detection in cases of doctor-shopping or diversion, but
its added value has not been evaluated.
A remaining challenge is that PDMPs do not identify patients who have not been
prescribed controlled substances in the past (opioid naïve) but may nevertheless
be at risk for substance use disorder based on other risk factors. It will be
important to assess whether a “clean” PDMP record can provide false reassurance
to providers for these patients, encouraging them to prescribe more liberally than
they otherwise would.
PDMPs will continue to evolve as important tools in state efforts to combat the
opioid epidemic. Best practices will evolve as well, as state programs mature and
evidence about effective processes and functionality expands. Although early
versions of PDMPs did not produce measurable changes in outcomes, they remain
a promising way to reduce morbidity and mortality from prescription opioid
misuse, while encouraging appropriate prescriptions for pain relief.
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